lifestyle.celebhomes.net
Home
Sample Page
Author:
BioInvent International
Resolutions at BioInvent’s Annual General Meeting 2026
April 29, 2026
BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio
April 29, 2026
BioInvent International AB: Interim Report January – March 2026
April 29, 2026
BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting
April 21, 2026
BioInvent International AB Publishes Annual Report 2025
March 31, 2026
BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis
March 26, 2026
BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer
January 5, 2026
BioInvent to Participate in Upcoming Investor Conference
December 20, 2025
BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025
December 8, 2025